BR112022010361A2 - Anticorpos biespecíficos com cisteínas de intercadeias combinadas alternativamente e usos dos mesmos - Google Patents

Anticorpos biespecíficos com cisteínas de intercadeias combinadas alternativamente e usos dos mesmos

Info

Publication number
BR112022010361A2
BR112022010361A2 BR112022010361A BR112022010361A BR112022010361A2 BR 112022010361 A2 BR112022010361 A2 BR 112022010361A2 BR 112022010361 A BR112022010361 A BR 112022010361A BR 112022010361 A BR112022010361 A BR 112022010361A BR 112022010361 A2 BR112022010361 A2 BR 112022010361A2
Authority
BR
Brazil
Prior art keywords
antibodies
alternatively combined
interchain cysteine
interchain
arm
Prior art date
Application number
BR112022010361A
Other languages
English (en)
Inventor
Chongyang Li Jack
Wang Minghan
Zou Hui
Jia Haiqun
Original Assignee
Phanes Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanes Therapeutics Inc filed Critical Phanes Therapeutics Inc
Publication of BR112022010361A2 publication Critical patent/BR112022010361A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTICORPOS BIESPECÍFICOS COM CISTEÍNAS DE INTERCADEIAS COMBINADAS ALTERNATIVAMENTE E USOS DOS MESMOS. A presente invenção refere-se a anticorpos biespecíficos modificados com ligação de dissulfeto intercadeia deslocada em um braço, mantendo a ligação de dissulfeto intercadeia original no segundo braço. Também são descritos anticorpos biespecíficos anti-CD47/FRa e fragmentos de ligação de antígeno destes. Também são descritos ácidos nucleicos codificando os anticorpos, composições compreendendo os anticorpos e métodos para produzir os anticorpos, bem como o uso de anticorpos para o tratamento ou prevenção de doenças, tal como câncer e/ou complicações associadas.
BR112022010361A 2019-12-17 2020-12-03 Anticorpos biespecíficos com cisteínas de intercadeias combinadas alternativamente e usos dos mesmos BR112022010361A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962948953P 2019-12-17 2019-12-17
US201962952747P 2019-12-23 2019-12-23
US202062988144P 2020-03-11 2020-03-11
US202063007996P 2020-04-10 2020-04-10
US202062704973P 2020-06-05 2020-06-05
US202062706511P 2020-08-21 2020-08-21
PCT/US2020/063066 WO2021126538A1 (en) 2019-12-17 2020-12-03 Bispecific antibodies with alternatively matched interchain cycteines and uses thereof

Publications (1)

Publication Number Publication Date
BR112022010361A2 true BR112022010361A2 (pt) 2022-08-16

Family

ID=76477869

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010361A BR112022010361A2 (pt) 2019-12-17 2020-12-03 Anticorpos biespecíficos com cisteínas de intercadeias combinadas alternativamente e usos dos mesmos

Country Status (11)

Country Link
US (1) US20220411497A1 (pt)
EP (1) EP4077377A1 (pt)
JP (1) JP2023511652A (pt)
KR (1) KR20220113991A (pt)
CN (1) CN114929739A (pt)
AU (1) AU2020404817A1 (pt)
BR (1) BR112022010361A2 (pt)
CA (1) CA3160436A1 (pt)
IL (1) IL293868A (pt)
MX (1) MX2022007513A (pt)
WO (1) WO2021126538A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024017371A1 (zh) * 2022-07-22 2024-01-25 信达生物制药(苏州)有限公司 促进多特异性抗体的重链和轻链同源配对的突变体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2925782T (pt) * 2012-12-03 2020-04-22 Novimmune Sa Anticorpos anti-cd47 e métodos de utilização destes
WO2017205014A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies

Also Published As

Publication number Publication date
CN114929739A (zh) 2022-08-19
MX2022007513A (es) 2022-07-05
IL293868A (en) 2022-08-01
WO2021126538A1 (en) 2021-06-24
KR20220113991A (ko) 2022-08-17
AU2020404817A1 (en) 2022-06-02
CA3160436A1 (en) 2021-06-24
EP4077377A1 (en) 2022-10-26
US20220411497A1 (en) 2022-12-29
JP2023511652A (ja) 2023-03-22

Similar Documents

Publication Publication Date Title
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
EA202091710A1 (ru) Антитела против cd73 и способы их применения
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
WO2018091740A3 (en) Novel anti_cd137 antibodies and uses thereof
MD4716B1 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
MX2018007406A (es) Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
EA202092735A1 (ru) Антагонизирующее cd73 антитело
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
CY1115349T1 (el) Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου
WO2015054600A3 (en) Glycan-interacting compounds and methods of use
EA201991059A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA202190807A1 (ru) Антитела к синуклеину
EA201691095A1 (ru) Мутантные фрагменты ospa и связанные с ними способы и применение
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз
EA201790437A1 (ru) Антигенсвязывающие белки, связывающиеся с cxcr3